Category Archives: Investment

Unknown Kentucky biotech Bexion tests new glioma med on first patients. Yes, it’s the same cancer Sen. McCain is fighting, and Round B funding is still open.

The News: Bexion Pharmaceuticals burst out of the shadows of near total obscurity last week as its investigational cancer treatment, BXQ-350, grabbed plenty of mainstream media coverage as a potential game-changer. BXQ-350 is… Read more »

Move over, Nasdaq: BeiGene’s mammoth IPO in Hong Kong sends message to biotech startups.

The News: Nasdaq-listed Chinese biotech BeiGene Ltd. (Beijing) has raised an astounding $903 million after pricing its secondary listing in Hong Kong–the first under new exchange rules–near the top of… Read more »

With a frenzy of popping corks and champagne toasts, Sangamo bags French biotech TxCell as Europe’s CAR T-cell science expanding into autoimmune disease. SGMA is a buy.

The News: Sangamo Therapeutics Inc. (Richmond CA) has acquired TxCell SA (Valbonne FRA) with a view toward utilizing its chimeric antigen receptor (CAR) technology to prevent organ transplant rejections and treat… Read more »

Healthcare IPOs defy gravity and second law of thermodynamics with 8 new pricings last week and 2 new filings.

Well, here we are again, looking back at another massive round of biotech IPOs priced just last week, as the beat goes on and on and… My trusty, hand-held calculator… Read more »

Top 1H health-sector winners and losers; buy/sell opinion.

The News: Now that we’ve reached the end of the first half of 2018, there might be some interesting surprises–both good and not-so-good–for those equity investors interested in who’s being… Read more »

Biotech IPOs smash record in H1, soaking up huge raises from the cash still parked on the sidelines. Will supply of buyers run out, like always?

The News: Last week the Nasdaq Biotech Index swooned 4% on Wednesday (July 27, 2018), only to rebound and halve that downdraft by Friday’s close (July 29, 2018). But despite… Read more »

Wondering why some of your Pharma shares keep going up? Thank Trump’s tax “reform;” no, really.

The News: The drug industry has taken heat from patient advocates and a US senator for handing out its tax savings to shareholders instead of using its windfall to help patients… Read more »

2018 biotech IPOs still on a tear, with 25 already priced; 8 new filings last week alone.

In all my 26 years at MondayMorning, never have I witnessed such a massive, mad dash for the IPO filing window, and the SEC must be wondering if and when… Read more »